Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EEF2K | O00418 | 16/20 | 1.00 |
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.48 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18186067 | 0.94 | EEF2K (0.89) | EEF2KMAPTALDH1A1MEN1GAA | |
| SCHEMBL4112027 | 0.81 | EEF2K (0.69) | EEF2KMAPTALDH1A1MEN1GAA | |
| SCHEMBL16888438 | 0.81 | EEF2K (0.68) | EEF2KMAPTALDH1A1MEN1GAA | |
| SCHEMBL16888392 | 0.76 | EEF2K (1.00) | EEF2KMAPTALDH1A1MEN1GAA | |
| SCHEMBL18186068 | 0.75 | EEF2K (0.60) | EEF2KMAPTALDH1A1MEN1GAA | |
| SCHEMBL16888437 | 0.74 | EEF2K (0.73) | EEF2KMAPTALDH1A1MEN1GAA | |
| SCHEMBL16888385 | 0.73 | EEF2K (1.00) | EEF2K | |
| SCHEMBL16888382 | 0.71 | EEF2K (1.00) | EEF2KMAPTALDH1A1MEN1GAA | |
| SCHEMBL16888391 | 0.71 | EEF2K (1.00) | EEF2KMAPTALDH1A1MEN1GAA | |
| SCHEMBL4105343 | 0.71 | ALDH1A1 (0.58) | EEF2KMAPTALDH1A1MEN1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160318948-A1 | Compounds Inhibiting Eukaryotic Elongation Factor 2 Kinase Activity | LONGEVICA PHARMACEUTICALS INC (US) | 2016-11-03 | — | — | US | disclosed |
| US-20160318948-A1 | Compounds Inhibiting Eukaryotic Elongation Factor 2 Kinase Activity | LONGEVICA PHARMACEUTICALS INC (US) | 2016-11-03 | — | — | US | disclosed |
| WO-2015102752-A1 | COMPOUNDS INHIBITING EUKARYOTIC ELONGATION FACTOR 2 KINASE ACTIVITY | LONGEVICA PHARMACEUTICALS, INC. (US) | 2015-07-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160318948-A1 | Compounds Inhibiting Eukaryotic Elongation Factor 2 Kinase Activity | EEF2K, EIF2AK1, EIF4EBP1 | EEF2K 1/4885MAPT 1525/4885ALDH1A1 4754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.